Glucose Elevating Agents Market
Number of pages: 100 | Report Format: PDF | Published date: May 02, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
CAGR |
6.3% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Products, Indication, Route of Administration, Distribution Channel and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global glucose elevating agents market is expected to register a revenue CAGR of 6.3% from 2023 to 2031.
Glucose Elevating Agents Market Fundamentals
Glucose elevating agents are substances that raise blood glucose levels. These medications treat hypoglycemia, insulinoma, and other diabetes-related conditions in people with low blood sugar levels. The glucose-elevating agents include glucagon, dextrose, and diazoxide. The precise medication is chosen based on the severity of hypoglycemia and the patient's medical history. Dextrose and diazoxide are used for less severe cases and can be consumed orally or injected intravenously. Glucagon is typically administered in emergencies if the patient cannot consume food or water. In addition, current research has proven that some vitamins and minerals may indirectly improve blood sugar regulation by influencing insulin sensitivity, glucose metabolism, and pancreatic function.
The industry is comprehensively analyzed in the glucose elevating agents industry analysis report, along with the factors that either aid or impede the market growth, such as its drivers, restraints, and opportunities. The research provides insight into the companies that operate in the glucose elevating agents market and their efforts to position themselves as key players through expansion strategies and innovations. It also highlights recent developments that contribute to the glucose elevating agents market growth. The research also analyzes the impact of the COVID-19 pandemic.
This research is valuable for businesses seeking insights into the market, customers, and competition. The research provides special insights into the segmentation, regions, market size & projection, revenue CAGRs, and other important information that may help clients make the right decisions. The report assembles data from market players and professionals across the industrial value chain. The study also incorporates qualitative and quantitative assessments from industry professionals. Secondary research, surveys and interviews, and statistical modeling are all used in our research to estimate market size and projection. Our reports deliver the most reliable market data because of our specialized research methods.
Glucose Elevating Agents Market Dynamics
Diabetes is a major risk factor for hypoglycemia, and the growing global prevalence of diabetes has increased the number of individuals at risk for hypoglycemia. With increased consumption of medications for diabetes, there is growing recognition of the risk of blood sugar levels dropping too low if the dosage is excessively high or if they are taken at the wrong time. Therefore, the increased tendency of medical non-adherence among people owing to their irregular lifestyle is a major contributor to supporting the glucose elevating agents market dynamics. Also, governments and non-government organizations worldwide are implementing policies and initiatives to address the growing burden of hypoglycemia and improve access to diagnosis, including the prevention and management of low blood sugar levels. These efforts have helped to drive the glucose elevating agents market growth. In addition, advancements in technology have also contributed to the market’s growth, with the development of continuous glucose monitoring systems and insulin pumps that can help individuals manage their blood sugar levels more effectively.
However, many glucose elevating agents, such as glucagon, can cause side effects such as nausea, vomiting, and increased heart rate, limiting their use and affecting patient adherence. Also, glucose elevating agents may not be effective in all individuals or all situations. They may not be able to elevate blood sugar levels to a safe range in severe cases of hypoglycemia which is considered the most important glucose elevating agents market challenge hindering sales.
Glucose Elevating Agents Market Ecosystem
Glucose Elevating Agents Market, by Products
Glucose Elevating Agents Market, by Indication
Glucose Elevating Agents Market, by Route of Administration
Glucose Elevating Agents Market, by Distribution Channel
Glucose Elevating Agents Market by Indication
[8565]
Based on the indications, the glucose elevating agents market is segmented into hypoglycemia, diabetic ketoacidosis, adrenal insufficiency, insulinoma, and others.
Hypoglycemia accounted for the largest revenue share of the market in terms of glucose elevating agents market forecast. In people with diabetes, hypoglycemia is a common complication of diabetes treatment, particularly in those who use insulin or certain oral medications. According to the American Diabetes Association, around 10% to 20% of people with type 1 diabetes experience severe hypoglycemia each year, while around 30% to 40% of people with type 2 diabetes who use insulin or sulfonylureas experience at least one episode of hypoglycemia per year. On the other hand, due to the increase in people leading sedentary lifestyles including lack of physical activity, excessive consumption of alcohol, and lack of medical adherence, the tendency to develop frequent drops in blood sugar level is the main reason providing lucrative opportunities to the glucose elevating agents market share.
The market segmentation sections provide the glucose elevating agents market outlook in terms of the demarcation of different consumer groups. Market segmentation is the splitting of an industry into subgroups depending on characteristics such as product, indication, route of administration and distribution channel. Market segmentation data helps organizations understand the preferences and distinctive demands of different customer groups and implement targeted marketing strategies. This data additionally helps in identifying potential glucose elevating agents market demand opportunities.
Glucose Elevating Agents Market by Region
Diabetes is one of the most prevalent diseases in North America, which increases the risk of hypoglycemia. As a result, a sizable patient group needs glucose elevating agents. In addition, from the glucose elevating agents market competitive landscape, North America is home to a number of significant market participants, which has fueled local innovation and product development. North America has a high level of awareness and education regarding diabetes and hypoglycemia, which has boosted demand for glucose-raising medications and enhanced patient outcomes. This glucose elevating agents market trend is expected to continue in the coming years as lifestyle changes and aging populations drive demand for these products.
Based on the regions, the global glucose elevating agents market is segmented into:
The industry's regional segmentation provides insights into geographic pockets in terms of glucose elevating agents industry trends, market size, share, and growth rate. This information helps organizations assess potential growth opportunities in new regional markets, understand competitive threats, and develop localized sales and expansion strategies. This section also offers deeper insights into the regional and country-level glucose elevating agents market overview.
Key Components of the Report
Glucose Elevating Agents Market Competitive Landscape
The glucose elevating agents market competitive landscape analysis is performed by gathering and evaluating data about the key competitors, industry trends, and market dynamics. It involves collecting and analyzing data on factors such as products, pricing, geographic reach, customer demographics, marketing tactics, and recent developments. Competitive landscape analysis can help organizations identify present or prospective opportunities and risks in the market.
Glucose Elevating Agents Market Strategic Development
Reasons To Buy This Report
Key Strengths of Our Report
Target Audience to Benefit from this Report.
Glucose elevating agents are medications or substances that are used to raise blood glucose levels in people with diabetes or other conditions that cause hypoglycemia.
North America will have the largest glucose elevating agents market size during the forecast period from 2023 to 2031.
The global glucose elevating agents market is expected to grow with revenue CAGR of 6.3% during the forecast period from 2023 to 2031.
The most prominent glucose elevating agents industry trend is developing new formulations of existing glucose elevating agents, which can raise the blood glucose level with a controlled concentration.
Increased research and development to invent new glucose elevating agents with lesser side effects are the major growth opportunities in the global glucose elevating agents market.
High cost and lack of awareness to use glucose elevating agents are the key challenges hampering the growth of the global glucose elevating agents market.
The major strategies key market players adopt involve strategic partnerships and collaborations to expand their market reach and capabilities.
Increased prevalence of diabetes and hypoglycemia are the drivers of the global glucose elevating agents market.
Key players in the global glucose elevating agents market are Par Pharmaceutical, Teva Pharmaceuticals USA, Inc., E5 Pharma Inc., Novitium Pharma, Eli Lilly and Company, Taj Pharmaceuticals Limited, and Global Calcium PVT LTD.
*Insights on financial performance are subject to the availability of information in the public domain